Physician profile
Michael Judd Davis
NPI 1720388069
$784.73
in general payments reported to CMS, 2019-2025
14 companies · $110 in 2025
The $110 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $131 · 2023: $289 · 2024: $255 · 2025: $110.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $654.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $653.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $195.51 | 2022-2025 | Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals LP | $122.14 | 2022-2024 | Farxiga, Airsupra |
| Novo Nordisk INC | $119.57 | 2023-2024 | Wegovy, Rybelsus, Ozempic |
| Dexcom, INC. | $76.13 | 2024-2025 | Dexcom G6 Transmitter |
| Glaxosmithkline, LLC. | $50.10 | 2022-2024 | Trelegy Ellipta |
| Azurity Pharmaceuticals, INC. | $41.90 | 2025 | Azmiro |
| Abbvie INC. | $34.72 | 2023 | Ubrelvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.90 | 2022 | |
| Pfizer INC. | $24.49 | 2023 | |
| Sanofi-Aventis U.S. LLC | $20.56 | 2024 | |
| Amarin Pharma, INC. | $20.19 | 2022 | |
| Edwards Lifesciences Corporation | $18.11 | 2022 | |
| Halozyme INC | $15.74 | 2023 | |
| Amgen INC. | $15.67 | 2025 | Evenity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.